Novartis India Ltd — Others, 04-07-2025: AGM/EGM

Novartis India Limited has announced a board meeting on July 31, 2025, to consider the financial results for the quarter and half-year. The Board has recommended a final dividend of ₹25 per equity share of face value ₹5, subject to shareholder approval. The company reported revenue from operations of ₹3,562.7 million, up 6.3%, and profit before tax at ₹1,304.2 million, reflecting operational efficiencies. Key segments include transplant immunology, established medicines, and neurosciences. Novartis India continues to focus on expanding access via AI integration, partnerships, and CSR initiatives, including vocational training for marginalized groups affected by leprosy. The Board proposes re-appointment of Mr. Falin Majmudar as Whole-Time Director and the appointment of M K Saraf & Associates LLP as Secretarial Auditors. The company maintains strong internal controls, compliance mechanisms, and is committed to sustainable business practices and corporate governance.